Article Versions Notes

Zhao JJ, Fong KY, Chan YH, Tey J, Dawood S, Lee SC, Finn RS, Sundar R, Lim JSJ. Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer. Cancers. 2023; 15(18):4558. https://doi.org/10.3390/cancers15184558

Zhao, Joseph J., Khi Yung Fong, Yiong Huak Chan, Jeremy Tey, Shaheenah Dawood, Soo Chin Lee, Richard S. Finn, Raghav Sundar, and Joline S. J. Lim. 2023. "Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer" Cancers 15, no. 18: 4558. https://doi.org/10.3390/cancers15184558

Zhao, J. J., Fong, K. Y., Chan, Y. H., Tey, J., Dawood, S., Lee, S. C., Finn, R. S., Sundar, R., & Lim, J. S. J. (2023). Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer. Cancers, 15(18), 4558. https://doi.org/10.3390/cancers15184558